Demographic, clinical, and treatment-related characteristics of patients with and without the prothrombin or factor V gene mutation
| . | No mutation (N = 186) . | FIIM (N = 24) . | FVM (N = 38) . | Combined mutation (N = 3) . |
|---|---|---|---|---|
| Age (y) (median, range) | 62 (23-86) | 52 (25-83) | 64 (23-87) | 45 (19-64) |
| Male sex (%) | 94 (51) | 12 (50) | 23 (61) | 2 (67) |
| PDD (d) (median, range) | 10 (1-52) | 7 (2-30) | 7 (1-30) | 12 (8-20) |
| Presentation of venous thrombosis | ||||
| idiopathic etiology (%) | 96 (77) | 8 (7) | 18 (15) | 2 (1.6) |
| secondary to risk factors (%) | 90 (71) | 16 (13) | 20 (16) | 1 (0.8) |
| Extent of DVT | ||||
| isolated distal (%) | 11 (6) | 1 (4) | 3 (8) | 0 (0) |
| proximal (%) | 175 (94) | 23 (96) | 35 (92) | 3 (100) |
| Duration of anticoagulant treatment | ||||
| 3 mo (%) | 179 (96) | 22 (92) | 34 (89) | 3 (100) |
| 6 mo (%) | 7 (4) | 2 (8) | 4 (11) | 0 (0) |
| . | No mutation (N = 186) . | FIIM (N = 24) . | FVM (N = 38) . | Combined mutation (N = 3) . |
|---|---|---|---|---|
| Age (y) (median, range) | 62 (23-86) | 52 (25-83) | 64 (23-87) | 45 (19-64) |
| Male sex (%) | 94 (51) | 12 (50) | 23 (61) | 2 (67) |
| PDD (d) (median, range) | 10 (1-52) | 7 (2-30) | 7 (1-30) | 12 (8-20) |
| Presentation of venous thrombosis | ||||
| idiopathic etiology (%) | 96 (77) | 8 (7) | 18 (15) | 2 (1.6) |
| secondary to risk factors (%) | 90 (71) | 16 (13) | 20 (16) | 1 (0.8) |
| Extent of DVT | ||||
| isolated distal (%) | 11 (6) | 1 (4) | 3 (8) | 0 (0) |
| proximal (%) | 175 (94) | 23 (96) | 35 (92) | 3 (100) |
| Duration of anticoagulant treatment | ||||
| 3 mo (%) | 179 (96) | 22 (92) | 34 (89) | 3 (100) |
| 6 mo (%) | 7 (4) | 2 (8) | 4 (11) | 0 (0) |
PDD, patient-doctor delay, defined as the period elapsed between occurrence of first symptoms and referral to thrombosis center.